ArticleJournal of Korean medical science2026
Seroepidemiological Study of Varicella Zoster Virus in Korea, 2023.
Article in Journal of Korean medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeroprevalence studies monitor changes in the immune status of populations. During the coronavirus disease 2019 (COVID-19) pandemic, public health measures such as social distancing and mask-wearing led to significant changes in the epidemiology and transmission patterns of many infectious diseases. In the post-pandemic period, outbreaks of various infectious diseases have been reported globally. In this context, this study evaluated changes in varicella zoster virus (VZV) seroepidemiology in the Republic of Korea after the COVID-19 pandemic.
methodsResidual serum samples were collected from specimens referred to Seoul Clinical Laboratories in 2023. Serum samples were collected after anonymization, with all identifiable information excluded except for date, age, sex, and region. Samples were collected evenly by age group in 5-year intervals. The evaluation of anti-VZV IgG antibodies was performed using a chemiluminescence immunoassay analyzer (Liaison
resultsThe study population comprised 995 participants including 581 males and 414 females. The overall VZV IgG seropositivity rate was 82.9%. The seropositivity rates of VZV IgG antibodies were 88.1% in males and 75.6% in females. VZV IgG seroprevalence showed variations across different age groups. VZV IgG seropositivity was 80% in the 1-4 year age group, declined to 53% in the 5-9 year age group, and reached its lowest at 43% in 10-14 year-olds. Seropositivity rates steadily increased from 71% in the 15-19 year-olds, to 85% in the 25-29 year group, and exceeded 95% in subjects ≥ 40 year of age.
conclusionSeropositivity rates in children (5-19 year) and adults (20-39 year) were lower than in previous studies in the Republic of Korea, likely due to reduced community exposure to varicella during the pandemic. These findings highlight a potential need to reinforce infection control measures and vaccination policies to address vulnerable age groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.